Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Quidel Surged 10% This Week

By Jason Hawthorne – Sep 2, 2021 at 6:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Demand for its COVID tests are rising with cases.

What happened

Shares of Quidel Corporation (QDEL) climbed 10% this week as of Thursday's close. Demand for at-home COVID testing is outstripping supply, with the delta variant pushing infections back to levels last seen in January.

A person in a bathroom reading an at-home COVID test.

Image source: Getty Images.

So what

Early last month, Quidel said sales in its fiscal second quarter declined 12% from the year earlier due in part to a drop-off in its COVID testing business. It doesn't appear that will be a problem next quarter as cases in the U.S. have climbed tenfold in the past two months. A company spokesperson said it is working with retailers to keep the company's QuickVue at-home test in stock.

One way it will do that is offering the test through the more than 7,000 CVS (CVS 0.92%) locations in the U.S. and online. The partnership was announced this Wednesday, and availability is expected within the next week.

Now what

The test maker is leaning into the surge by ramping up manufacturing lines that had been repurposed when COVID waned. Other test makers Abbott Labs (ABT 0.15%) and Becton Dickinson (BDX 0.62%) had also curbed production this summer.

Another driver of demand is the return of students to classrooms and workers to office buildings. With many organizations implementing policies that require constant testing in lieu of vaccination, the surge in sales may remain elevated unless vaccination rates improve.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Quidel. The Motley Fool recommends Becton, Dickinson and CVS Health. The Motley Fool has a disclosure policy.

Stocks Mentioned

Quidel Stock Quote
Quidel
QDEL
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$108.09 (0.15%) $0.16
Becton, Dickinson And Stock Quote
Becton, Dickinson And
BDX
$252.38 (0.62%) $1.55
Cvs Health Stock Quote
Cvs Health
CVS
$102.58 (0.92%) $0.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.